“To take or not to take an aspirin?” The age-old question of cardiovascular disease primary prevention for people with chronic kidney disease
Despite the higher risk of cardiovascular events in patients with chronic kidney disease, the role of aspirin for primary prevention is unclear. In the current issue, Wolfe et al. present a subgroup analysis of the ASPirin in Reducing Events in the Elderly (ASPREE) trial that suggests there was no reduction in cardiovascular events but bleeding events were doubled. Aspirin cannot be recommended for primary prevention in chronic kidney disease, but the continuation of on going research, such as the Aspirin To Target Arterial Events in Chronic Kidney Disease (ATTACK trial), is warranted.
Source: Kidney International - Category: Urology & Nephrology Authors: Rupert W. Major, James O. Burton Tags: Commentary Source Type: research
More News: Aspirin | Bleeding | Cardiology | Cardiovascular | Chronic Kidney Disease | Heart | Urology & Nephrology